Valuation: Compass Therapeutics, Inc.

Market Cap 14Cr 13Cr 12Cr 11Cr 20Cr 1.37TCr 21Cr 143.19Cr 56Cr 716.32Cr 54Cr 53Cr 2.27TCr P/E 2026 *
-1.62x
P/E 2027 * -1.43x
Enterprise Value -56.6L -50.52L -46.6L -42.34L -79.43L -54Cr -80.65L -5.61Cr -2.21Cr -28Cr -2.12Cr -2.08Cr -89Cr EV / Sales 2026 *
-
EV / Sales 2027 * 1.74x
Free-Float
87.53%
Yield 2026 *
-
Yield 2027 * -
1 day-1.60%
1 week-10.62%
Current month-22.93%
1 month-35.36%
3 months-60.71%
6 months-84.93%
Current year-85.07%
1 week 0.78
Extreme 0.7801
0.89
1 month 0.78
Extreme 0.7801
1.2
Current year 0.78
Extreme 0.7801
6.88
1 year 0.78
Extreme 0.7801
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 28/05/2024
Director of Finance/CFO 54 09/12/2024
Chief Tech/Sci/R&D Officer 50 01/01/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2014
Director/Board Member 64 01/01/2015
Chairman 61 01/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Buy

Controller/Auditor

20,000 0.0111%
24/09/26 Buy

Controller/Auditor

2,500 0.0014%
29/04/26 Buy

Controller/Auditor

15,000 0.0083%
Change 5-day change 1-year change 3-year change Capi.($)
-1.60%-10.62%-80.73%-59.52% 14Cr
-4.10%-8.54%+40.05%+66.99% 6.33TCr
-0.49%+7.06%+10.56%+72.77% 5.49TCr
-0.25%+3.61%+9.02%+91.03% 5.33TCr
+0.61%+2.69%+27.75%+50.97% 4.58TCr
-1.08%+2.19%+21.92%+131.38% 4.35TCr
-3.39%-0.83%+254.27%+571.04% 4.02TCr
-1.67%+6.70%+14.42%+56.67% 3.35TCr
+1.19%-4.98%+29.01%-0.76% 2.37TCr
-1.11%+5.12%+35.71%+26.87% 2.38TCr
Average -1.21%-0.65%+36.20%+100.74% 3.82TCr
Weighted average by Cap. -1.36%+0.59%+47.26%+122.01%

Financials

2026 *2027 *
Net sales - 65.12L 58.13L 53.62L 48.72L 91.4L 62Cr 92.8L 6.46Cr 2.54Cr 32Cr 2.44Cr 2.39Cr 102.38Cr
Net income -9.33Cr -8.32Cr -7.68Cr -6.98Cr -13Cr -883.45Cr -13Cr -93Cr -36Cr -462.85Cr -35Cr -34Cr -1.47TCr -11Cr -9.97Cr -9.2Cr -8.36Cr -16Cr -1.06TCr -16Cr -110.82Cr -44Cr -554.39Cr -42Cr -41Cr -1.76TCr
Net Debt -15Cr -13Cr -12Cr -11Cr -21Cr -1.42TCr -21Cr -148.8Cr -59Cr -744.41Cr -56Cr -55Cr -2.36TCr -13Cr -12Cr -11Cr -9.95Cr -19Cr -1.26TCr -19Cr -131.94Cr -52Cr -660.04Cr -50Cr -49Cr -2.09TCr
Projected Income Statement - Annual - Compass Therapeutics, Inc.
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
22/26/22 $0.8015 -1.60% 21,73,546
21/26/21 $0.8145 -2.26% 15,44,138
20/26/20 $0.8333 -0.20% 18,83,132
19/26/19 $0.8350 -2.91% 31,19,040
16/26/16 $0.8600 -4.09% 20,38,934
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Compass Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
0.8015USD
Average target price
5.455USD
Spread / Average Target
+580.54%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Compass Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CMPX Stock